What is the recommended therapy for pembrolizumab‑induced pneumonitis that is refractory to two weeks of high‑dose steroids (1 g intravenous methylprednisolone for three days followed by prednisone 1 mg/kg) and a course of intravenous immunoglobulin 2 g/kg?

Steroid-Refractory Pembrolizumab-Induced Pneumonitis: Next-Line Therapy

For pembrolizumab-induced pneumonitis that has failed both high-dose steroids and IVIG, you should add infliximab (5 mg/kg IV) or consider cyclophosphamide, though mortality remains extremely high (67-100%) at this stage. 1

Recommended Treatment Algorithm

First-Line Additional Immunosuppression (After Steroid + IVIG Failure)

The ASCO 2021 guidelines explicitly address this scenario for Grade 3-4 pneumonitis 1:

• Infliximab: Standard dosing at 5 mg/kg IV
• Alternative: Cyclophosphamide - particularly if infliximab is contraindicated or unavailable
• Continue high-dose steroids during additional immunosuppression (do not taper yet)
• Plasmapheresis: Can be considered as an alternative to IVIG or infliximab 1

Critical Management Points

Permanently discontinue pembrolizumab - this should have already occurred, but ensure it is documented 1.

ICU-level monitoring is mandatory given the severity and steroid-refractory nature 1. Your patient likely requires:

• Continuous pulse oximetry
• Frequent pulmonary function assessment
• Daily clinical review for progression

Steroid taper timing: Begin 3-4 weeks after initiation of the additional immunosuppressant, then wean based on symptom improvement 1. Do not taper prematurely as this increases recurrence risk.

Evidence Quality and Nuances

The Infliximab Controversy

There is concerning data about infliximab in this setting. A 2021 retrospective study found 100% mortality (5/5 patients) in those treated with infliximab for steroid-refractory ICI-pneumonitis 2. However, this may reflect selection bias - infliximab was used in the most severe cases, particularly those with diffuse alveolar damage (DAD) pattern.

One case report showed transient improvement with infliximab, but the patient ultimately died from re-exacerbation 3. The authors suggested that repeated infliximab dosing (second dose at 2 weeks) might be necessary, though current guidelines don't recommend this 3.

IVIG Outcomes

Since you've already administered IVIG without response, the prognosis is concerning. The same 2021 study found that IVIG alone had 43% mortality in steroid-refractory cases - better than infliximab but still substantial 2. Combination IVIG + infliximab showed 100% mortality 2, so adding infliximab after IVIG failure is particularly high-risk.

Cyclophosphamide as Alternative

Emerging evidence suggests cyclophosphamide may be superior to infliximab in this setting:

• A 2022 French registry study found that among patients requiring second-line immunosuppression, the two survivors at 5 months were both treated with cyclophosphamide 4
• A 2020 case report demonstrated successful treatment with triple therapy (high-dose steroids + tacrolimus + cyclophosphamide) for steroid-refractory pneumonitis with DAD pattern 5
• This regimen is borrowed from treatment of clinically amyopathic dermatomyositis (CADM) with pulmonary complications 5

Practical Recommendations

If Choosing Infliximab:

• Dose: 5 mg/kg IV 1
• Consider repeat dosing at 2 weeks if initial response followed by deterioration 3
• Monitor closely for infectious complications (major cause of death in this population) 2

If Choosing Cyclophosphamide:

• Consider pulse cyclophosphamide (500-1000 mg/m² IV monthly) 4, 5
• May add tacrolimus (target trough 5-10 ng/mL) for triple therapy in severe cases 5
• This approach may have better outcomes than infliximab based on limited data 4

Prognostic Considerations

Your patient's prognosis is grave. The overall mortality for steroid-refractory ICI-pneumonitis requiring second-line immunosuppression is 67-100% 4, 2. Poor prognostic features include:

• DAD radiographic pattern (most common in steroid-refractory cases - 50%) 2
• Need for mechanical ventilation
• Early onset (typically after mean of 5 ICI doses) 2
• Failure of both steroids and IVIG

Common Pitfalls

1. Premature steroid taper: Wait 3-4 weeks after starting additional immunosuppression 1
2. Underestimating infection risk: Infectious complications are a major cause of death - maintain high suspicion and low threshold for broad-spectrum antibiotics 2
3. Delay in escalation: Once steroids fail at 48 hours, additional immunosuppression should be initiated promptly 1
4. Single-dose infliximab: Consider repeat dosing if transient improvement occurs 3

Given the failure of both steroids and IVIG, cyclophosphamide-based therapy may offer better outcomes than infliximab based on the limited available evidence, though both options carry extremely high mortality risk 4, 2.